Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study
暂无分享,去创建一个
J. D. Engel | J. Engel | J. Jacobberger | Y. Saunthararajah | D. Lavelle | M. Phelps | J. Tisdale | V. Gordeuk | T. Radivoyevitch | L. Hsu | K. Ng | M. Hsieh | R. Molokie | M. A. Ruiz | V. Ibanez | J. Desimone | M. Pacini | M. Gowhari | L. Krauz | Johara Hassan | P. Woost | Daisy Pacelli | Sherry Fada | Matthew Rump | Santhosh Saraf | Michel Gowhari
[1] Gabriel S. Eichler,et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. , 2010, Cancer research.
[2] C. Dampier,et al. Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. , 2001, Blood.
[3] M. Pembrey,et al. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. , 2020, Annals of internal medicine.
[4] Peter A. Jones,et al. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors , 2009, Epigenetics.
[5] A. Smaldone,et al. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use , 2016, Pediatric blood & cancer.
[6] S. Kuentzel,et al. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice. , 1975, Cancer chemotherapy reports.
[7] A. Nienhuis,et al. Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. , 1993, The New England journal of medicine.
[8] R. Molokie,et al. Tetrahydrouridine, cytidine analogues, and hemoglobin F , 1985, American journal of hematology.
[9] C. Pegelow,et al. Hydroxyurea and sickle cell anemia: effect on quality of life , 2006, Health and quality of life outcomes.
[10] B. Rini,et al. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. , 2012, Seminars in oncology.
[11] T. Orfeo,et al. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. , 2012, Blood.
[12] Matthieu Defrance,et al. The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent , 2016, Oncotarget.
[13] M. Goodman,et al. Embryonic ε and γ globin genes of a prosimian primate (Galago crassicaudatus): Nucleotide and amino acid sequences, developmental regulation and phylogenetic footprints , 1988 .
[14] S. Orkin,et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. , 1984, The Journal of clinical investigation.
[15] R. Hoffman,et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.
[16] M. Biel,et al. Maintenance of fetal hemoglobin (HbF) elevations in the baboon by prolonged erythropoietic stress. , 1982, Blood.
[17] D. Budman,et al. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin , 2004, Cancer Chemotherapy and Pharmacology.
[18] Nita Ahuja,et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.
[19] Paola Sebastiani,et al. Fetal hemoglobin in sickle cell anemia. , 2011, Blood.
[20] M L Terrin,et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.
[21] H. Patscheke,et al. In‐vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with β‐thalassaemia major , 1997, British journal of haematology.
[22] J. D. Engel,et al. Fine Tuning of Globin Gene Expression by DNA Methylation , 2006, PloS one.
[23] M L Terrin,et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. , 1997, Blood.
[24] R. Momparler,et al. Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). , 2013, Leukemia research.
[25] M. Goodman,et al. Embryonic epsilon and gamma globin genes of a prosimian primate (Galago crassicaudatus). Nucleotide and amino acid sequences, developmental regulation and phylogenetic footprints. , 1988, Journal of molecular biology.
[26] E Vichinsky,et al. Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.
[27] D. Labie,et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[28] B. Setty,et al. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. , 2000, Blood.
[29] M. Steinberg. Hydroxyurea Treatment for Sickle Cell Disease , 2002, TheScientificWorldJournal.
[30] R. Flavell,et al. DNA methylation in the human gamma delta beta-globin locus in erythroid and nonerythroid tissues. , 1980, Cell.
[31] Stephen M. Johnson,et al. Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia , 2011, American journal of hematology.
[32] Richard D Moore,et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. , 1992, Blood.
[33] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[34] D. Zwiers,et al. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[35] B. Ramsahoye,et al. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme , 2010, Nucleic acids research.
[36] Ming Zhao,et al. Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura , 2006, Clinical Cancer Research.
[37] A. Chuansumrit,et al. Platelet counts in thalassemic children before and after splenectomy. , 1993, The Southeast Asian journal of tropical medicine and public health.
[38] J. Cannon,et al. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. , 1973, Biochemical pharmacology.
[39] N. Mahmud,et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. , 2004, Blood.
[40] A. Nienhuis,et al. Treatment with Azacitidine of Patients with End-Stage β-Thalassemia , 1993 .
[41] J. Christman,et al. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. , 1982, The Journal of biological chemistry.
[42] K. Mann. Prothrombin activation. , 1974, Human pathology.
[43] Y. Saunthararajah,et al. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects , 2012, Oncotarget.
[44] K. Mann,et al. The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells , 2013, Journal of thrombosis and haemostasis : JTH.
[45] T. Ley,et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. , 1982, The New England journal of medicine.
[46] P. Swerdlow. Red cell exchange in sickle cell disease. , 2006, Hematology. American Society of Hematology. Education Program.
[47] T. Lumley,et al. Platelet count and the risk for thrombosis and death in the elderly , 2009, Journal of thrombosis and haemostasis : JTH.
[48] J. Schellens,et al. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study , 2012, Cancer Chemotherapy and Pharmacology.
[49] J. Maciejewski,et al. p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia , 2011, Leukemia.
[50] George J. Dover,et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments] , 1992 .
[51] J. Byrd,et al. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method , 2007, Nucleic acids research.
[52] M. Egorin,et al. Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine , 2008, Clinical Cancer Research.
[53] O. Platt,et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.
[54] W. Schroeder,et al. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? , 1984, Blood.
[55] D. Lavelle,et al. On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation. , 1986, Blood.
[56] J. Maciejewski,et al. Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus , 2010, Molecular Cancer Therapeutics.
[57] F. Barton,et al. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea , 1999, British journal of haematology.
[58] J. Freyssinet,et al. Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia , 2008, Haematologica.
[59] R. Ware,et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. , 2002, Blood.
[60] G. de Haan,et al. Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. , 1997, Blood.
[61] H. Leonhardt,et al. Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation , 2007, Nucleic acids research.
[62] P. Frenette,et al. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. , 2016, Blood.
[63] P. Atadja,et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. , 2007, Blood.
[64] G. Dover,et al. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. , 1985, Blood.
[65] N. Goldschmidt,et al. Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells , 2008, Thrombosis and Haemostasis.
[66] Y. Saunthararajah,et al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. , 2012, Blood.
[67] R. Riccardi,et al. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. , 1982, Cancer research.
[68] S. Kriaucionis,et al. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer , 2015, Nature.
[69] James Douglas Engel,et al. Nuclear Receptors TR2 and TR4 Recruit Multiple Epigenetic Transcriptional Corepressors That Associate Specifically with the Embryonic β-Type Globin Promoters in Differentiated Adult Erythroid Cells , 2011, Molecular and Cellular Biology.
[70] A. Schechter,et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. , 1983, Blood.
[71] B. Skikne,et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] S. Baylin,et al. DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes , 2012, Nucleic acids research.
[73] T. Woodcock,et al. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man. , 1977, Cancer treatment reports.
[74] D. Matei,et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer , 2010, Cancer.
[75] B. Rini,et al. Noncytotoxic differentiation treatment of renal cell cancer. , 2011, Cancer research.
[76] Y. Saunthararajah,et al. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo , 2012, International journal of cancer.
[77] I. Aban,et al. Severe anemia early in life as a risk factor for sickle-cell kidney disease. , 2017, Blood.
[78] C. Kidson. Trade, population flow and transnation malaria control. , 1993, The Southeast Asian journal of tropical medicine and public health.
[79] J. Smith,et al. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. , 1992, Journal of clinical epidemiology.
[80] G. Dover,et al. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[81] V. Heinemann,et al. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. , 1989, Biochemical pharmacology.
[82] P. Barr,et al. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs , 1983, Cell.
[83] A. Schechter,et al. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease , 2001, Current opinion in hematology.
[84] C. Moore,et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension , 2008, Haematologica.
[85] R. Benjamin,et al. Clinical Pharmacology of Tetrahydrouridine , 1978 .
[86] Goldenthal Ei,et al. Preclinical toxicologic evaluation of tetrahydrouridine (NSC-112907) in beagle dogs and rhesus monkeys. , 1974 .
[87] M. Gladwin,et al. Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens! , 2008, Haematologica.
[88] D. Budman,et al. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. , 1991, Leukemia.
[89] C. Pegelow,et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.
[90] M. Grever,et al. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. , 2006, Rapid communications in mass spectrometry : RCM.
[91] Y. Saunthararajah,et al. Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease , 2011, British journal of haematology.
[92] Y. Saunthararajah,et al. DNA hypo‐methylating agents and sickle cell disease , 2004, British journal of haematology.
[93] J. Desimone,et al. Magnitude of the fetal hemoglobin response to acute hemolytic anemia in baboons is controlled by genetic factors. , 1980, The Journal of clinical investigation.
[94] P. Nordlund,et al. CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil , 2016, Nature Communications.
[95] J. Desimone,et al. Stimulation of fetal hemoglobin synthesis in baboons by hemolysis and hypoxia. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[96] Y. Saunthararajah,et al. Subchronic Oral Toxicity Study of Decitabine in Combination With Tetrahydrouridine in CD-1 Mice , 2014, International journal of toxicology.
[97] J. Desimone,et al. Hemopoietic stress and fetal hemoglobin synthesis: comparative studies in vivo and in vitro. , 1979, Blood.
[98] J. Maciejewski,et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. , 2015, The Journal of clinical investigation.
[99] R. Flavell,et al. DNA methylation in the human γδβ-globin locus in erythroid and nonerythroid tissues , 1980, Cell.
[100] R. Benjamin,et al. Clinica, pharmacology of tetrahydrouridine. , 1978, Journal of clinical pharmacology.
[101] Bruce Barton,et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. , 2006, JAMA.
[102] Y. Saunthararajah. Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. , 2013, Hematology. American Society of Hematology. Education Program.
[103] A. Jankowska,et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors , 2011, Leukemia.
[104] C. G. Smith,et al. Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. , 1967, Biochemical pharmacology.
[105] C. Haywood,et al. Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005 , 2013, Public health reports.
[106] I. Wistuba,et al. Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas , 2009, Clinical Cancer Research.
[107] J. Niland,et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. , 1991, Annals of internal medicine.
[108] A. Carè,et al. Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[109] M. Goldberg,et al. Participation of hemoglobins A and F in polymerization of sickle hemoglobin. , 1977, The Journal of biological chemistry.
[110] F. Trachtenberg,et al. A pilot study of subcutaneous decitabine in β-thalassemia intermedia. , 2011, Blood.
[111] D. Zwiers,et al. Genetic Relationship between Fetal Hb Levels in Normal and Erythropoietically Stressed Baboons , 1981, British journal of haematology.
[112] Steven S. Foster,et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair , 2010, Proceedings of the National Academy of Sciences.
[113] K. Kohn,et al. Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. , 1986, Cancer research.
[114] S. Chuncharunee,et al. Etiology and incidence of thrombotic and hemorrhagic disorders in Thai patients with extreme thrombocytosis. , 2000, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[115] D. Lavelle,et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. , 2002, Blood.
[116] M. Cappellini,et al. Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma , 2009, Haematologica.
[117] S. Orkin,et al. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A , 2013, Proceedings of the National Academy of Sciences.
[118] A. Tefferi. Platelet count in essential thrombocythemia: the more the better? , 2008, Blood.
[119] D. Santi,et al. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[120] D. Weatherall,et al. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. , 1963, Blood.
[121] G. Mufti,et al. Histone Deacetylase Inhibitors (HDI) Cause DNA Damage in Leukemia Cells: A Mechanism for Leukemia-Specific HDI-Dependent Apoptosis? , 2006, Molecular Cancer Research.
[122] J. Burchenal,et al. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. , 1979, Cancer treatment reports.
[123] I. Bhan,et al. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin , 2012, British journal of haematology.
[124] V. Velcheti,et al. Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.